Comparison of demographics, clinical, and echocardiographic characteristics between patients who experienced death or hospitalization for congestive heart failure (composite outcome) and those who remained event-free during follow-up.
| . | Event-free patients (n = 215) . | Composite outcome (n = 81) . | P-value . |
|---|---|---|---|
| Follow-up (months) | 68 (32–84) | 2 (1–13) | <0.001 |
| Age (years) | 50 (32–67) | 76 (60–82) | <0.001 |
| Sex (male, %) | 106 (49.3) | 30 (37) | 0.059 |
| Body surface area (m2) | 1.75 (1.61–1.88) | 1.71 (1.61–1.85) | 0.299 |
| NYHA class | <0.001 | ||
| I | 190 (88) | 31 (38) | |
| II | 19 (9) | 34 (42) | |
| III | 6 (3) | 16 (20) | |
| Heart rate (bpm) | 68 (61–80) | 72 (65–85) | 0.008 |
| Atrial fibrillation, n (%) | 40 (19) | 51 (63) | <0.0001 |
| Systolic blood pressure (mmHg) | 120 (110–140) | 120 (110–140) | 0.769 |
| Diastolic blood pressure (mmHg) | 70 (70–80) | 70 (60–80) | 0.370 |
| PASP (mmHg) | 25 (21–35) | 48 (36–80) | <0.001 |
| LV ejection fraction (%) | 62 (57–65) | 59 (54–62) | 0.002 |
| RV end-diastolic volume (mL/m2) | 70 (56–91) | 90 (70–124) | <0.001 |
| RV end-systolic volume (mL/m2) | 32 (24–50) | 52 (37–80) | <0.001 |
| RV stroke volume (mL/m2) | 37 (30–46) | 38 (32–44) | 0.697 |
| RV ejection fraction (%) | 53 (46–58) | 43 (34–50) | <0.001 |
| RV basal diameter (mm/m2) | 23 (21–26) | 27 (25–31) | <0.001 |
| Right atrial volume (mL/m2) | 34 (27–40) | 63 (41–75) | <0.001 |
| Other significant valvular heart diseases | 5 (2) | 5 (7) | 0.102 |
| TR PISA radius (mm) | 2 (1–4) | 8 (6–9) | <0.001 |
| TR VCavg (mm) | 2 (1–4) | 8 (5–10) | <0.001 |
| TR EROA (cm2) | 0.02 (0.01–0.12) | 0.36 (0.20–0.49) | <0.001 |
| TR RegVol (mL) | 2 (0.5–12) | 39 (26–49) | <0.001 |
| TR RegFr (%) | 3 (1–16) | 57 (42–71) | <0.001 |
| TR severity15,16 | <0.001 | ||
| Mild, n (%) | 182 (85) | 14 (17) | |
| Moderate, n (%) | 27 (13) | 29 (36) | |
| Severe, n (%) | 6 (3) | 38 (47) |
| . | Event-free patients (n = 215) . | Composite outcome (n = 81) . | P-value . |
|---|---|---|---|
| Follow-up (months) | 68 (32–84) | 2 (1–13) | <0.001 |
| Age (years) | 50 (32–67) | 76 (60–82) | <0.001 |
| Sex (male, %) | 106 (49.3) | 30 (37) | 0.059 |
| Body surface area (m2) | 1.75 (1.61–1.88) | 1.71 (1.61–1.85) | 0.299 |
| NYHA class | <0.001 | ||
| I | 190 (88) | 31 (38) | |
| II | 19 (9) | 34 (42) | |
| III | 6 (3) | 16 (20) | |
| Heart rate (bpm) | 68 (61–80) | 72 (65–85) | 0.008 |
| Atrial fibrillation, n (%) | 40 (19) | 51 (63) | <0.0001 |
| Systolic blood pressure (mmHg) | 120 (110–140) | 120 (110–140) | 0.769 |
| Diastolic blood pressure (mmHg) | 70 (70–80) | 70 (60–80) | 0.370 |
| PASP (mmHg) | 25 (21–35) | 48 (36–80) | <0.001 |
| LV ejection fraction (%) | 62 (57–65) | 59 (54–62) | 0.002 |
| RV end-diastolic volume (mL/m2) | 70 (56–91) | 90 (70–124) | <0.001 |
| RV end-systolic volume (mL/m2) | 32 (24–50) | 52 (37–80) | <0.001 |
| RV stroke volume (mL/m2) | 37 (30–46) | 38 (32–44) | 0.697 |
| RV ejection fraction (%) | 53 (46–58) | 43 (34–50) | <0.001 |
| RV basal diameter (mm/m2) | 23 (21–26) | 27 (25–31) | <0.001 |
| Right atrial volume (mL/m2) | 34 (27–40) | 63 (41–75) | <0.001 |
| Other significant valvular heart diseases | 5 (2) | 5 (7) | 0.102 |
| TR PISA radius (mm) | 2 (1–4) | 8 (6–9) | <0.001 |
| TR VCavg (mm) | 2 (1–4) | 8 (5–10) | <0.001 |
| TR EROA (cm2) | 0.02 (0.01–0.12) | 0.36 (0.20–0.49) | <0.001 |
| TR RegVol (mL) | 2 (0.5–12) | 39 (26–49) | <0.001 |
| TR RegFr (%) | 3 (1–16) | 57 (42–71) | <0.001 |
| TR severity15,16 | <0.001 | ||
| Mild, n (%) | 182 (85) | 14 (17) | |
| Moderate, n (%) | 27 (13) | 29 (36) | |
| Severe, n (%) | 6 (3) | 38 (47) |
EROA, effective regurgitant orifice area; LV, left ventricular; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; PISA, proximal isovelocity surface area; RegFr, regurgitant fraction; RegVol, regurgitant volume; RV, right ventricular; TR, tricuspid regurgitation; VCavg, vena contracta width.
Comparison of demographics, clinical, and echocardiographic characteristics between patients who experienced death or hospitalization for congestive heart failure (composite outcome) and those who remained event-free during follow-up.
| . | Event-free patients (n = 215) . | Composite outcome (n = 81) . | P-value . |
|---|---|---|---|
| Follow-up (months) | 68 (32–84) | 2 (1–13) | <0.001 |
| Age (years) | 50 (32–67) | 76 (60–82) | <0.001 |
| Sex (male, %) | 106 (49.3) | 30 (37) | 0.059 |
| Body surface area (m2) | 1.75 (1.61–1.88) | 1.71 (1.61–1.85) | 0.299 |
| NYHA class | <0.001 | ||
| I | 190 (88) | 31 (38) | |
| II | 19 (9) | 34 (42) | |
| III | 6 (3) | 16 (20) | |
| Heart rate (bpm) | 68 (61–80) | 72 (65–85) | 0.008 |
| Atrial fibrillation, n (%) | 40 (19) | 51 (63) | <0.0001 |
| Systolic blood pressure (mmHg) | 120 (110–140) | 120 (110–140) | 0.769 |
| Diastolic blood pressure (mmHg) | 70 (70–80) | 70 (60–80) | 0.370 |
| PASP (mmHg) | 25 (21–35) | 48 (36–80) | <0.001 |
| LV ejection fraction (%) | 62 (57–65) | 59 (54–62) | 0.002 |
| RV end-diastolic volume (mL/m2) | 70 (56–91) | 90 (70–124) | <0.001 |
| RV end-systolic volume (mL/m2) | 32 (24–50) | 52 (37–80) | <0.001 |
| RV stroke volume (mL/m2) | 37 (30–46) | 38 (32–44) | 0.697 |
| RV ejection fraction (%) | 53 (46–58) | 43 (34–50) | <0.001 |
| RV basal diameter (mm/m2) | 23 (21–26) | 27 (25–31) | <0.001 |
| Right atrial volume (mL/m2) | 34 (27–40) | 63 (41–75) | <0.001 |
| Other significant valvular heart diseases | 5 (2) | 5 (7) | 0.102 |
| TR PISA radius (mm) | 2 (1–4) | 8 (6–9) | <0.001 |
| TR VCavg (mm) | 2 (1–4) | 8 (5–10) | <0.001 |
| TR EROA (cm2) | 0.02 (0.01–0.12) | 0.36 (0.20–0.49) | <0.001 |
| TR RegVol (mL) | 2 (0.5–12) | 39 (26–49) | <0.001 |
| TR RegFr (%) | 3 (1–16) | 57 (42–71) | <0.001 |
| TR severity15,16 | <0.001 | ||
| Mild, n (%) | 182 (85) | 14 (17) | |
| Moderate, n (%) | 27 (13) | 29 (36) | |
| Severe, n (%) | 6 (3) | 38 (47) |
| . | Event-free patients (n = 215) . | Composite outcome (n = 81) . | P-value . |
|---|---|---|---|
| Follow-up (months) | 68 (32–84) | 2 (1–13) | <0.001 |
| Age (years) | 50 (32–67) | 76 (60–82) | <0.001 |
| Sex (male, %) | 106 (49.3) | 30 (37) | 0.059 |
| Body surface area (m2) | 1.75 (1.61–1.88) | 1.71 (1.61–1.85) | 0.299 |
| NYHA class | <0.001 | ||
| I | 190 (88) | 31 (38) | |
| II | 19 (9) | 34 (42) | |
| III | 6 (3) | 16 (20) | |
| Heart rate (bpm) | 68 (61–80) | 72 (65–85) | 0.008 |
| Atrial fibrillation, n (%) | 40 (19) | 51 (63) | <0.0001 |
| Systolic blood pressure (mmHg) | 120 (110–140) | 120 (110–140) | 0.769 |
| Diastolic blood pressure (mmHg) | 70 (70–80) | 70 (60–80) | 0.370 |
| PASP (mmHg) | 25 (21–35) | 48 (36–80) | <0.001 |
| LV ejection fraction (%) | 62 (57–65) | 59 (54–62) | 0.002 |
| RV end-diastolic volume (mL/m2) | 70 (56–91) | 90 (70–124) | <0.001 |
| RV end-systolic volume (mL/m2) | 32 (24–50) | 52 (37–80) | <0.001 |
| RV stroke volume (mL/m2) | 37 (30–46) | 38 (32–44) | 0.697 |
| RV ejection fraction (%) | 53 (46–58) | 43 (34–50) | <0.001 |
| RV basal diameter (mm/m2) | 23 (21–26) | 27 (25–31) | <0.001 |
| Right atrial volume (mL/m2) | 34 (27–40) | 63 (41–75) | <0.001 |
| Other significant valvular heart diseases | 5 (2) | 5 (7) | 0.102 |
| TR PISA radius (mm) | 2 (1–4) | 8 (6–9) | <0.001 |
| TR VCavg (mm) | 2 (1–4) | 8 (5–10) | <0.001 |
| TR EROA (cm2) | 0.02 (0.01–0.12) | 0.36 (0.20–0.49) | <0.001 |
| TR RegVol (mL) | 2 (0.5–12) | 39 (26–49) | <0.001 |
| TR RegFr (%) | 3 (1–16) | 57 (42–71) | <0.001 |
| TR severity15,16 | <0.001 | ||
| Mild, n (%) | 182 (85) | 14 (17) | |
| Moderate, n (%) | 27 (13) | 29 (36) | |
| Severe, n (%) | 6 (3) | 38 (47) |
EROA, effective regurgitant orifice area; LV, left ventricular; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; PISA, proximal isovelocity surface area; RegFr, regurgitant fraction; RegVol, regurgitant volume; RV, right ventricular; TR, tricuspid regurgitation; VCavg, vena contracta width.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
